May 18, 2020
Global Focal Segmental Glomerulosclerosis (FSGS) Industry Report 2020 - Epidemiology, Pipeline, Drugs, KOL Views, Companies and Outlook to 2030
Feb 19, 2020
ChemomAb Ltd. Announces Issuance of Composition of Matter Patent for CM-101 and Reinforces its IP Portfolio
Oct 21, 2019
Focal Segmental Glomerulosclerosis (FSGS) Market Insights, Epidemiology, and Market Forecasts, 2028
Dec 20, 2018
NeuroRx Research Developed Novel Brain MRI Measures of Chronic Lesion Activity and Progressive Pathology in People With Multiple Sclerosis
Oct 30, 2018
Variant Pharmaceuticals Submits Application for U.S. Orphan Drug Designation for VAR 200 (2-Hydroxypropyl-b-Cyclodextrin) To Treat Focal Segmental Glomerulosclerosis (FSGS)
Oct 24, 2018
Variant Pharmaceuticals Announces Publication of Data Demonstrating 2-Hydroxypropyl-b-Cyclodextrin (2HPbCD) Protects Against Kidney Disease in Experimental Models of Alport Syndrome (AS) and Focal Segmental Glomerulosclerosis (FSGS)
Oct 16, 2018
Variant Pharmaceuticals Receives Notice of Allowance in Two U.S. Patent Applications Covering Lead Compound, 2-hydroxypropyl-b-cyclodextrin, a Phase 2a-ready Asset for Rare Renal Disease, Focal Segmental Glomerulosclerosis (FSGS)
Jul 26, 2018
12 Major Medical Research Centers Partner with the Scleroderma Research Foundation to "CONQUER" Scleroderma - an Often Lethal Autoimmune Disease
Apr 30, 2018
Tuberous Sclerosis Complex Global Awareness Day Scheduled for May 15
Apr 16, 2018
Variant Pharmaceuticals Completes Pre-IND Meeting with FDA on VAR 200 for Focal Segmental Glomerulosclerosis (FSGS), a Rare Kidney Disease
Jan 24, 2018
Focal Segmental Glomerulosclerosis Market to Reach US$15.83 Billion by 2025, Globally: Transparency Market Research
Jan 04, 2018
Tuberous Sclerosis Alliance Announces New Global Partnership in Hungary
Jun 07, 2017
Soin Neuroscience Files An Orphan Drug Application To Treat Systemic Sclerosis